Cambridge Investment Research Advisors’s Enovix ENVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$119K Sell
19,531
-3,000
-13% -$19.9K ﹤0.01% 3913
2026
Q1
$117K Buy
22,531
+2,959
+15% +$18.5K ﹤0.01% 3774
2025
Q4
$143K Sell
19,572
-19,468
-50% -$189K ﹤0.01% 3647
2025
Q3
$389K Sell
39,040
-19,059
-33% -$211K ﹤0.01% 2892
2025
Q2
$526K Sell
58,099
-18,573
-24% -$121K ﹤0.01% 2506
2025
Q1
$492K Buy
76,672
+10,313
+16% +$91.8K ﹤0.01% 2458
2024
Q4
$631K Buy
66,359
+1,198
+2% +$10.5K ﹤0.01% 2239
2024
Q3
$533K Buy
65,161
+15,062
+30% +$156K ﹤0.01% 2359
2024
Q2
$678K Buy
50,099
+25,361
+103% +$212K ﹤0.01% 2052
2024
Q1
$173K Sell
24,738
-8,053
-25% -$69.9K ﹤0.01% 3059
2023
Q4
$359K Sell
32,791
-4,732
-13% -$46.5K ﹤0.01% 2462
2023
Q3
$412K Buy
37,523
+3,434
+10% +$49.1K ﹤0.01% 2241
2023
Q2
$538K Buy
+34,089
New +$397K ﹤0.01% 2076

Other funds holding ENVX

Cambridge Investment Research Advisors's ENVX Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Enovix (ENVX) stake by 13% in Q2 2026, selling an estimated $19.9K and leaving 19,531 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #3913.

Cambridge Investment Research Advisors first reported a position in ENVX in Q2 2023 and has held it in 13 quarters since. The position peaked at $678K in Q2 2024. 298 funds tracked by Wall St. Rank hold ENVX as of Q2 2026.

  • Cambridge Investment Research Advisors held 19,531 shares of Enovix worth $119K as of Q2 2026.
  • Cambridge Investment Research Advisors sold 3,000 Enovix shares in Q2 2026, an estimated $19.9K.
  • Enovix made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3913 holding.
  • Cambridge Investment Research Advisors first reported a position in Enovix in Q2 2023 and has held it in 13 quarters since.
  • Cambridge Investment Research Advisors's Enovix position peaked at $678K in Q2 2024.
  • 298 funds tracked by Wall St. Rank held Enovix as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.